HTS Phenotypic Screening Services

High-throughput screening is an efficient means to rapidly identify promising compounds, but what happens when you get poor data? Unanticipated results can derail your program or force a total restart, wasting your resources. Get protection from the unpredictability of science and make the most of your high-throughput screening investment by working with a flexible, collaborative partner who lets you know the minute the unexpected occurs and makes the necessary adjustments to optimize your program and keep you on track.

Whether you’re targeting oncology, neuroscience, rare disease, inflammation, musculoskeletal disease, cardiovascular disease, or other systems, you’ll benefit from our vast compound libraries for the identification of hit compounds, and from our experience with challenging targets and assay systems.

Hit Discovery Results

Our robust quality management system (QMS) and assay validation procedures generate high quality data processed through IDBS, Titian, and Dotmatics software suites to ensure the accurate and confidential transfer of your high-throughput screening data.

HTS Assay Flexibility

We can screen your libraries with a capacity of up to 1 million compounds in single compound format, or up to 3 million in compressed formats, and can store a copy of your library for multiple screening campaigns.

Hit Expansion

Maximize your high-throughput screening investment. Enlarge your pool of active compounds and gain early structure-activity relationship (SAR) data with our cost-effective hit expansion service.

Ask us a question about your screen

High-Throughput Mass Spectrometry for Phenotypic Screening

Generating rich, multi-parametric data that is highly reproducible, high-throughput mass spectrometry (HTMS) is an indispensable tool for hit identification. The label-free biochemical and cell-based screens of HTMS reduce false positives by eliminating artifacts introduced by fluorescent tags.

Applied in screening, hit confirmation, and ADME, HTMS offers the advantage of direct detection without the use of surrogates, radioactivity, or coupled assays. Charles River offers HTMS on high-capacity equipment, paired with the added flexibility of column chromatography.

By examining chemical motifs and scaffolds found to have activity in the primary high- throughput screen, we can mine our extensive compound collection and select sets of related compounds for follow-on screening. This helps to rapidly identify additional hits and new scaffolds, as well as build SAR around existing hits. These additional compound sets are identified using 2D and 3D similarity and pharmacophore searching.